Whitehawk Therapeutics (WHWK) Insider Zhao Buys 38,040 Shares
Insider Baiteng Zhao bought 38,040 shares of Whitehawk Therapeutics on June 12, 2026, at a price of $4.1 each.
Reviewed by automated data checks against the source filing. How we make and check alerts
Baiteng Zhao bought 38,040 shares of Whitehawk Therapeutics, Inc. ($WHWK) on June 12, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $WHWK is up 7.2% after 1 week, down 7.7% after 1 month and down 30.5% to date (from the $4.16 close on Jun 12, 2026).
WHWK
Whitehawk Therapeutics, Inc.
Key Points
- On June 12, 2026, insider Baiteng Zhao bought 38,040 shares of Whitehawk Therapeutics, priced at $4.1 each.
- The stock is currently trading around $4.1, close to its 52-week high of $5.50.
- Analysts have a consensus buy rating on Whitehawk Therapeutics, with targets ranging from $4 to $10.
Get $WHWK trade alerts by text
We text you when insiders, Congress or big funds trade $WHWK. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Whitehawk Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Whitehawk Therapeutics, Inc.
On June 12, 2026, insider Baiteng Zhao bought 38,040 shares of Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK) at a price of $4.1 per share. This purchase reflects a significant investment in the company, which is involved in developing oncology therapeutics. The total value of this transaction was not disclosed, but it shows Zhao's confidence in the company's future prospects.
Other Insiders Join Zhao in Buying Shares
Baiteng Zhao wasn't the only insider to purchase shares on June 12. Mohammad Hirmand, Behzad Aghazadeh, Richard Maroun, Emma Reeve, Neil Desai, and Caley Castelein each bought 38,040 shares on the same day. This collective buying activity suggests strong belief among the leadership in the company's direction and its ongoing projects.
Stock Performance and Market Context
As of June 12, 2026, Whitehawk Therapeutics shares were trading at $4.1. This position is just below its 52-week high of $5.50, indicating that the stock has seen significant interest and movement in the market. The stock's performance is noteworthy as it approaches this high, reflecting investor sentiment and the company's potential in the biotechnology sector.
Analysts Set New Price Targets
Analysts have recently shown a positive outlook on Whitehawk Therapeutics. On June 25, 2026, B. Riley Securities reiterated a buy rating with a price target of $10. Following that, on July 13, 2026, Leerink Partners initiated coverage with an outperform rating and a target of $9. Most recently, on October 1, 2026, Stifel also initiated coverage with a buy rating, setting a target price of $9. The average target price among analysts is around $9. This consensus suggests confidence in the company's potential for growth.
What Whitehawk Therapeutics, Inc. Does
Whitehawk Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative cancer treatments. With a portfolio of next-generation antibody drug conjugates, the company aims to advance cancer therapies. This insider buying activity, along with recent analyst ratings, highlights the company's promising future in the healthcare sector.
What's Ahead for Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics is set to report its next earnings on November 5, 2026. As the company continues to develop its oncology projects, further insider transactions and analyst ratings will be worth monitoring. The recent insider buying reflects a strong belief in the company, but as always, past transactions may not represent current positions.
Related Filing Alerts
Source: Baiteng Zhao's Form 4 filing on $WHWK (Jun 12, 2026). Find the original filing: WHWK Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts